Immuno Oncology

• FDA Approves LIBTAYO® in Combination with Chemotherapy for Non-Small Cell Lung Cancer

• TAFINLAR® and MEKINIST® versus OPDIVO® plus YERVOY® for Patients with Advanced BRAF-Mutant Melanoma: The DREAMseq Trial

• Association of Gut Microbiome with Immune Checkpoint Inhibitor Response in Advanced Melanoma

• FDA Approves TECVAYLI® for Relapsed or Refractory Multiple Myeloma

• FDA Approves IMJUDO® plus IMFINZI® for Patients with Advanced Hepatocellular Carcinoma

• OPDIVO® (nivolumab) for the Adjuvant Treatment of High-Risk Urothelial Carcinoma*

• Late Breaking Abstract – ESMO 2022: PADCEV® plus KEYTRUDA® in Previously Untreated Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer

• Late Breaking Abstract – ESMO 2022: Neoadjuvant KEYTRUDA® with Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma

• Late Breaking Abstract – ESMO 2022: CABOMETYX®, OPDIVO® and YERVOY® in Previously Untreated Advanced Renal Cell Carcinoma

• FDA Approves IMFINZI® in Combination with Chemotherapy for Advanced Biliary Tract Cancer

• Opdualag™ (nivolumab and relatlimab-rmbw): A New Dual I-O Option in the 1L Treatment of Metastatic Melanoma

• Late Breaking Abstract – ASCO 2022: Landmark Five Year Overall Survival Rates for OPDIVO® and YERVOY® Combination in NSCLC

• FDA Approves OPDIVO® Combination for Advanced Esophageal Carcinoma

• FDA Approves KYMRIAH® for Relapsed or Refractory Follicular Lymphoma

• IMFINZI® in Combination with Chemotherapy Improves Overall Survival in Advanced Biliary Tract Cancer

• Mutations of STK11/KRAS Genes and Efficacy of Immunotherapy in NSCLC

• IMFINZI® Plus Tremelimumab Significantly Improves Overall Survival in Advanced Hepatocellular Carcinoma

• OPDIVO® (nivolumab) + chemotherapy (fluoropyrimidine + platinum-based) for the first-line (1L) treatment of metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma, regardless of PD-L1 status

• FDA Approves Neoadjuvant OPDIVO® and Chemotherapy Combination for Early Stage Non Small Cell Lung Cancer

• FDA Approves YESCARTA® for Second Line Treatment of Large B-cell Lymphoma